Celera and Merck link up on Alzheimer's:
This article was originally published in Clinica
Celera Diagnostics has joined forces with Merck & Co to identify novel targets for drug discovery and diagnostic markers related to Alzheimer's disease. Alameda, California-based Celera will conduct a functional genome scan to pinpoint novel gene variations associated with the disease, and will retain rights for diagnostic applications from the studies. Merck will receive rights for therapeutic applications from the studies in Alzheimer's disease, as well as for certain other neurological disorders. It will also fund discovery research at Celera related to the collaboration, and will make certain clinical milestone payments and pay a royalty on sales of pharmaceutical products it commercialises as a result of the study.
You may also be interested in...
Italy Round-Up: Mylan And Polifarma Strike Deal, OTC Market Stable, Cholesterol-Lowering Probiotic Launch
The latest news from Italy's OTC and supplements markets, including the latest sales figures, business deals, product launches, ad regulation and local association activities.
Sandoz CEO Richard Saynor has pledged that the company will ensure stable pricing for essential coronavirus-related medicines amid concerns over how the outbreak will affect the supply chain.
Executives On The Move: Comings And Goings At Atara Biothera And Pfizer, Along With A Promotion At Domainex
T-cell immunotherapy firm Atara Biotherapeutics decides on a chief commercial officer and Pfizer oncology R&D head leaves for CSO spot at Vividion Therapeutics. Also, COO of UK drug discovery CRO Domainex is set to climb to CEO position.